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Abstract
Heparanase is an endoglycosidase that specifically
cleaves heparan sulfate (HS) side chains of HS pro-
teoglycans, themajor proteoglycans in the extracellular
matrix and cell surfaces. Traditionally, heparanase ac-
tivity was implicated in cellular invasion associated
with angiogenesis, inflammation, and cancer metas-
tasis. More recently, heparanase upregulation was
documented in an increasing number of primary human
tumors, correlating with reduced postoperative sur-
vival rate and enhanced tumor angiogenesis. In the
present study, we examined the expression of hepa-
ranase in squamous cell carcinoma of the head and
neck by means of immunostaining, and we correlated
expression levels with patient outcome. The intensity
and extent of heparanase staining correlated with
tumor stage (P = .049 and P = .027, respectively), and
the extent of staining further correlated with tumor
grade (P = .047). Moreover, heparanase expression
inversely correlated with patient status at the end of the
study (P = .012). Notably, heparanase localization was
found to be an important parameter for patient status.
Thus, 63% of patients with nuclear staining, compared
to 19% of patients with cytoplasmic staining (P = .0043),
were alive, indicating that nuclear localization of the
enzyme predicts a favorable outcome.
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Introduction
Squamous cell carcinoma of the head and neck (SCCHN)
continues to be the sixth most common neoplasm in the
world, where > 500,000 new cases are projected annually
[1]. Approximately 200,000 deaths occur yearly as a result of
cancer of the oral cavity and pharynx, and the outcome has
not improved significantly in the past 25 years [2]. Tumor
metastases are common among patients with head and
neck cancer with uncontrolled local or regional disease,
and autopsy studies revealed a 40% to a 47% overall incidence
of distantmetastases [3,4]. The incidence of distantmetastases
among patients who remain free of disease at local and re-
gional sites is lower (18–20%) although still significant.With im-
provement in locoregional control of advanced head and neck
cancer resulting from new treatment regimens, distant failure
has emerged as the most common reason for disease recur-
rence [5,6]. Therapies for advanced SCCHN include combined
chemoradiotherapy. Emerging evidence suggests the effec-
tiveness of anti–epidermal growth factor receptor therapy,
combined with chemotherapy and/or radiation [2]. Clearly, a
better understanding of the molecular biology of head and neck
tumors is required to define relevant targets and to develop
novel therapeutic approaches.
Heparanase is an endoglycosidase that specifically cleaves
heparan sulfate (HS) side chains of HS proteoglycans [7–9],
the major proteoglycans in the extracellular matrix (ECM) and
cell surfaces [10,11]. In addition to its structural role as a mo-
lecular link between different ECM components, contributing
to ECM integrity and insolubility, HS side chains can bind a
variety of biologic mediators, such as growth factors, cytokines,
and chemokines, thus forming a readily available reservoir
that can be liberated on local or systemic cues [12–15].
Traditionally, heparanase activity was implicated in cellular
invasion associated with angiogenesis, inflammation, and
cancer metastasis [16–20]. This notion gained further support
by employing siRNA and ribozyme technologies, clearly de-
picting heparanase-mediated HS cleavage and ECM remodel-
ing as critical requisites for metastatic spread [21]. Recently,
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heparanase upregulation was documented in an increasing
number of primary human tumors. Heparanase upregulation
correlated with reduced postoperative survival of pancreatic
[22,23], bladder [24], gastric [25,26], cervical [27], and colo-
rectal [28] cancer patients. Moreover, heparanase upregu-
lation correlated with increased lymph node and distant
metastases [23–26], providing strong clinical support for
the prometastatic feature of heparanase. Similarly, hepa-
ranase upregulation was noted in head and neck tumors
[29,30], yet studies examining a large number of tumor
samples of this cancer have not been reported. Here, we
examined heparanase expression in a cohort of head and
neck patients and correlated clinical–pathological data with
heparanase immunostaining and cellular localization. We
report that heparanase expression correlates with head
and neck tumor progression. Cytoplasmic staining of hepa-
ranase inversely correlates with patient survival and pre-
dicts poor prognosis, whereas nuclear heparanase predicts
a favorable outcome.
Materials and Methods
Experimental Design
The study included 74 patients with head and neck cancer
who were diagnosed at the Department of Otolaryngology,
Head andNeckSurgery, CarmelMedical Center (Haifa, Israel)
whose archival paraffin-embedded pathological specimens
were available for immunohistochmical analysis. The study
protocol was approved by the Institutional Review Board.
The clinical data of all patients were reviewed, and patients
were restaged according to the American Joint Committee of
Cancer 2003 staging system. Clinical data included demo-
graphics, tumor site, tumor–node–metastasis staging, treat-
ment modality, status at the end of the study (dead or alive),
failure (local, regional, or distant), time to failure, follow-up, and
survival. Pathological data included histology, tumor grade,
local and regional spread of the disease (pT and pN), and
extracapsular extension (ECE).
Heparanase Immunostaining
Staining of formalin-fixed, paraffin-embedded, 5-mm sec-
tions for heparanase was performed essentially as described
[31,32]. Briefly, slides were deparaffinized and rehydrated,
and endogenous peroxidase activity was quenched (for
30 minutes) by 3% hydrogen peroxide in methanol. Slides
were then subjected to antigen retrieval by boiling (for
20 minutes) in 10 mM citrate buffer, pH 6. Slides were in-
cubated with 10% normal goat serum in phosphate-buffered
saline (PBS) for 60 minutes to block nonspecific binding
and were incubated (20 h, 4jC) with anti–heparanase 733
antibody diluted 1:100 in blocking solution. Antibody 733
was raised in rabbits against a 15-amino-acid peptide
(KKFKNSTYSRSSVDC) that maps at the N-terminus of a
50-kDa heparanase subunit and preferentially recognizes
the 50-kDa heparanase subunit versus a 65-kDa latent pro-
enzyme [31]. Slides were extensively washed with PBS
containing 0.01% Triton X-100 and incubated with a sec-
ondary reagent (Envision kit; Dako, Glostrup, Denmark)
according to the manufacturer’s instructions. Following ad-
ditional washes, color was developed with AEC reagent
(Dako), and sections were counterstained with hematoxylin
and mounted, as described [31]. Immunostained specimens
were examined by senior pathologists (E.S. and I.N.) blinded
to the clinical data of patients and were scored according
to intensity of staining (0 = none; 1 = weak–moderate; 2 =
strong) and the percentage (extent staining) of tumor cells
that were stained (0, < 10%; 1, 10–50%; 2, > 50%). Speci-
mens that were similarly stained with preimmune serum or
application of the above procedure without the primary anti-
body yielded no detectable staining. For statistical analysis,
we combined cases diagnosed as negative heparanase
staining with cases diagnosed as weak heparanase staining
compared to cases with strong heparanase intensity and/or
extent (subgroups 0 and 1 vs subgroup 2).
Statistical Analysis
Univariate associations between heparanase parameters
(intensity and extent of staining) and clinical and pathological
findings, as well as patient outcome, were analyzed using chi-
square test (Pearson and Fisher’s exact test). Multivariable
logistic regression was performed to detect independent
parameters that affect patient status and to estimate relevant
odds ratio (OR) with 95% confidence interval (95% CI).
Univariate association with survival and cause-specific sur-
vival was evaluated by Kaplan-Meier curves and tested
using log-rank test. A multivariable Cox’s proportional hazard
model was performed with stepwise selection to identify
independent predictors of survival and cause-specific sur-
vival (P for enter and P to stay were set at .1). The model
included all parameters with P < .2 by univariate analysis.
Results
We have developed a polyclonal antibody (pAb no. 733) that
preferentially recognizes the 50-kDa heparanase subunit
over the latent 65-kDa proenzyme [31]. Thus, immuno-
staining of archival material can be correlated with hepa-
ranase enzymatic activity. We employed antibody 733 to
examine heparanase expression in specimens collected
from head and neck cancer patients. Seventy-four patients
(68 males and 6 females) were included in this study (the
median age at diagnosis was 66.7 ± 12 years). The mean
follow-up was 43.9 ± 6.04 months for the entire group and
64.8 ± 11.05 months for patients who are still alive. A clini-
cal description of patients is presented in Table 1. Larynx
was the predominant site (77%; 57 of 74), followed by the
pharynx, oral cavity, carcinoma with unknown primary origin,
and others. Most patients had advanced disease, as indi-
cated by T (primary tumor) and N (nodal metastasis) staging
criteria (Table 1), because patients with early disease were
treated with radiotherapy and tumor specimens were not
available. Neck dissection was carried out in 35 patients.
Metastatic nodes were found in 30 specimens: 13 with one
node and 17 with two or more metastatic nodes. ECE was
observed in 14 metastatic specimens.
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Expression and Cellular Localization of Heparanase
Positive heparanase staining was found in 86% (64 of 74)
of tumor specimens (Figure 1B), whereas 14% (10 of 74) of
the specimens were negative (Figure 1A). The heparanase-
positive group was further categorized according to the in-
tensity and extent of staining (Table 2). Thus, weak staining
(+1) was found in 58% (37 of 64) of positive specimens,
whereas 42% (27 of 64) stained strongly (+2) for heparanase
(Table 2, Figure 1). According to the extent criteria (see
Materials and Methods section), 81% (52 of 64) of the speci-
mens that positively stained for heparanase were scored as
high extent (+2), whereas the rest 19% were scored as low
extent. Heparanase expression in terms of intensity and,
even more so, extent positively correlated with head and
neck tumor progression (P = .049 and .027, respectively;
Table 2). For example, although only 50% of the tumors that
expressed no or low levels of heparanase were diagnosed
as T3–4, 81% of the tumors with strong heparanase staining
were diagnosed as such (Table 2, extent). A similar trend was
notedwith respect to the intensity criterion (Table 2, intensity).
Moreover, the extent of heparanase staining also correlated
with tumor grade (P = .047; Table 2), further supporting a role
for heparanase in head and neck tumor progression. A close
examination of the heparanase-positive group revealed a
distinct cellular localization pattern (Figure 1). Thus, in 50%
of the specimens (32 of 64), heparanase staining appeared
Figure 1. Immunohistochemical staining of heparanase in SCCHN tumor specimens. Formalin-fixed, paraffin-embedded, 5-m sections of head and neck tumors
were subjected to immunostaining of heparanase by applying anti –heparanase 733 antibody, as described under Materials and Methods section. Shown are
representative photomicrographs of heparanase-negative (A) and heparanase-positive (B–D) specimens: (B) cytoplasmic; (C) nuclear; and (D) cytoplasmic and
nuclear. Specimens that were similarly stained with preimmune serum (E) or application of the above procedure but without the primary antibody (F) yielded no
detectable staining. (A–D) Original magnification, 400; (E and F) original magnification, 200.
Table 1. Clinical Description of Patients (n = 74).
Parameter Patients [n (%)]
Site of tumor
Larynx 57 (77)
Pharynx 6 (8)
Oropharynx 4
Hypopharynx 2
Oral cavity 3 (4)
Other 8 (11)
T stage
T0 – 2 21 (28)
T3 29 (39)
T4 24 (33)
N stage
N0 39 (53)
N1 8 (11)
N2 – 3 27 (36)
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cytoplasmic (Figure 1B); in 12.5% (8 of 64), heparanase
was found in the cell nucleus (Figure 1C); and, in the rest of
the specimens, 37.5% (24 of 64) of heparanase-positive
specimens assumed both nuclear and cytoplasmic localiza-
tion (Figure 1D).
Prognostic Value of Heparanase for Head and
Neck Carcinomas
To determine the prognostic value of heparanase for
SCCHN, we analyzed patient status, cumulative survival,
and cause-specific survival according to heparanase ex-
pression levels and localization. The extent of heparanase
expression inversely correlated with patient status (P = .011;
Table 3, Figure 2), and a similar trend was noted for the
intensity of staining, although borderline significant (P = .085;
Table 3). Even more impressive was the correlation between
the cellular localization of heparanase and patient outcome.
Clearly, patients with nuclear staining had an outcome better
than that of patients with cytoplasmic staining. Although 63%
of patients assuming nuclear staining survived, only 19% of
patients exhibiting cytoplasmic staining and 54% of cases
with both nuclear and cytoplasmic staining were alive at the
end of the study (P = .0043; Table 3, Figure 3). For further
analysis, we combined the patients with nuclear heparanase
staining with those with both nuclear and cytoplasmic stain-
ings and compared them to patients with cytoplasmic stain-
ing only. We further employed multivariate logistic regression
analysis to examine the contribution of different parameters
to patient status (including T and N stages), heparanase
staining intensity, extent, and cellular localization (Table 4).
The most significant and independent parameter that in-
fluenced patient status was heparanase localization (cyto-
plasmic versus nuclear, P = .002), followed by T stage
(P = .006) (Table 4). Univariate analysis of overall survival
and cause-specific survival was similarly performed for clin-
ical, pathological (T and N stages, ECE), and heparanase
staining parameters. Patients exhibiting nuclear localization
Table 2. Association of Heparanase Intensity and Extent of Staining with
T Stage and Tumor Grade (Univariate Analysis).
T Stage T0 – 2 [n (%)] T3 – 4 [n (%)] Total P
Heparanase intensity
0 5 (50) 5 (50) 10 .049
1 12 (32) 25 (68) 37
2 4 (15) 23 (85) 27
Total 21 53 74
Heparanase extent
0 5 (50) 5 (50) 10 .027
1 6 (50) 6 (50) 12
2 10 (19) 42 (81) 52
Total 21 53 74
Grade Carcinoma In Situ and
Well-Differentiated
Carcinoma [n (%)]
Moderately to
Poorly Differentiated
Carcinoma [n (%)]
Heparanase extent
0–1 8 (40) 12 (60) 20 .047
2 9 (18) 42 (82) 51
Total 17 52 71
Heparanase intensity: 0 = no staining; 1 = weak to moderate staining; 2 =
strong staining.
Heparanase extent: 0, < 10% staining; 1, 10–50% staining; 2, > 50% staining.
Patients with no heparanase staining (0) were combined with the low-
expressing group (1) for statistical analysis.
Table 3. Heparanase Parameters in Correlation with Patient Status.
Alive [n (%)] Died [n (%)] Total P
Heparanase intensity
0 7 (70) 3 (30) 10 .085
1 16 (43) 21 (57) 37
2 8 (30) 19 (70) 27
Heparanase extent
0 7 (70) 3 (30) 10 .0116
1 8 (67) 4 (33) 12
2 16 (31) 36 (69) 54
Heparanase localization
Nuclear/cytoplasmic
0 7 (70) 3 (30) 10 .0043
Nuclear 5 (63) 3 (37) 8
Nuclear + cytoplasmic 13 (54) 11 (46) 24
Cytoplasmic 6 (19) 26 (81) 32
Figure 2. Cause-specific survival (Kaplan-Meier survival plot) stratified by
extent of heparanase staining. Note that patients with low levels of hepa-
ranase staining (< 10%) had a 5-year cause-specific survival of 100%.
Figure 3. Survival analysis. Overall survival stratified by nuclear versus
cytoplasmic staining of heparanase (Kaplan-Meier survival plot). Log-rank
test, P = .03.
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of heparanase had significantly higher overall survival at
5 years (69%) than patients with only cytoplasmic staining
(26%) (P = .03; Table 5, Figure 3). For cause-specific sur-
vival, the N stage (P = .0007), ECE (P = .0006), and nuclear
localization of heparanase (P = .04) were the most significant
parameters. Cox’s proportional hazard model was subse-
quently performed for overall survival and included all hepa-
ranase parameters and clinical parameters (Tstage, N stage,
heparanase extent staining, and localization; Table 6). The
analysis was adjusted to the age of the patients at diag-
nosis. The most significant independent parameters that in-
fluenced the overall survival of SCCHN patients included
heparanase localization (P = .007, for cytoplasmic versus
nuclear staining), age at the time of diagnosis (P = .008),
T stage (P = .07), and N stage (P = .08) (Table 6). Cox’s
proportional hazard model for cause-specific survival of the
group revealed that the most significant parameters are
N stage (P = .002) and heparanase staining extent (P = .05)
(Table 7). Age was not a significant independent parameter
for cause-specific survival. Thus, both the extent of staining
and the localization of heparanase are critical parameters for
the survival of SCCHN patients. These results indicate that
heparanase cellular localization stands as an independent
parameter for the overall survival of head and neck cancer
patients and supports a role for heparanase in the progres-
sion of SCCHN, suggesting that the enzyme is a valid target
for the development of anticancer drugs and, possibly, is a
diagnostic marker for this malignancy.
Discussion
SCCHN is characterized by poor prognosis due to aggres-
sive tumor growth and high rate of tumor cell dissemination
[1]. In spite of improved treatment, the outcome of SCCHN
patients did not improve significantly in the past 25 years
[1,2], clearly implying a need for a better understanding of
cellular andmolecular aspects of this malignancy to establish
better therapeutic modalities. Here, we examined the ex-
pression of heparanase in biopsy specimens derived from
74 SCCHN patients, using immunohistochemistry. The anti–
heparanase 733 antibody employed has been previously
shown to preferentially recognize the 50-kDa heparanase
subunit versus the 65-kDa latent protein [31]. The 50-kDa
subunit comprises, together with an 8-kDa subunit, the active
enzyme heterodimer [33–35], so that positive staining with
the 733 antibody most likely correlates with heparanase
enzymatic activity. This antibody was successfully employed
to study heparanase expression and regulation by nasopha-
ryngeal and colon carcinomas [32,36], supporting its diag-
nostic potential. Heparanase upregulation was noted in
the majority (82%) of the SCCHN specimens examined, in
agreement with heparanase overexpression found in many
other human cancers [37,38]. Importantly, intensity and, even
more so, the extent (i.e., percentage of positively stained
cells) of heparanase staining correlated with the progression
Table 4. Multivariate Logistic Regression for Patient Status at the End of the
Study (Dead or Alive).
Term OR 95% CI P
Heparanase localization:
cytoplasmic/nuclear
2.4 1.36–4.35 .0023
T stage (3/4–0/1/2) 5.3 1.65–18.36 .0068
OR, odds ratio; CI, confidence interval.
Table 5. Univariate 5-Year Overall Survival and Cause-Specific Survival
Analyses Including Clinical and Heparanase Parameters.
Parameter 5-Year
Cause-Specific
Survival (%)
P 5-Year
Overall
Survival (%)
P Patients
at Risk
T stage
T0 – 2 68 .1 59 .08 21
T3 46 37 29
T4 66 28 24
N stage
N0 76 .0007 47 .096 39
N1 44 31 8
N2 – 3 28 26 27
ECE
Without ECE 73 .0006 55 .0005 21
With ECE 30* 24* 14
Heparanase intensity
0 100 .13 44 .4 10
1 58 41 37
2 47 34 27
Heparanase extent
0 100 .11 44 .19 10
1 69 69 12
2 51 33 52
Heparanase localization
0 100 .04 44 .03 10
Nuclear and
nuclear +
cytoplasmic
60 69 32
Cytoplasmic 47 26 32
Statistical significance was tested using the log-rank test.
*Survival estimated at 24 months.
ECE, extracapsular extension.
Table 6. Cox’s Proportional Hazard Model for Overall Survival: Hazard Ratio
and 95% CI of All Independent Parameters.
Parameter Hazard Ratio P 95% CI
Heparanase localization:
cytoplasmic/nuclear
2.42 .007 1.27–4.62
Age 1.04 .008 1.01–1.07
T stage .075
T3 vs T0– 2 2.24 .12 0.81–6.02
T4 vs T0– 2 3.16 .024 1.16–8.58
N stage .08
N1 vs N0 1.24 .68 0.45–3.39
N2 vs N0 2.27 .025 1.1–4.66
Table 7. Cox’s Proportional Hazard Model for Cause-Specific Survival:
Hazard Ratio and 95% CI of Independent Parameters.
Parameter Hazard Ratio P 95% CI
N stage .002
N1 vs N0 3.42 .078 0.87–13.4
N2 vs N0 5.23 .001 2.05–13.3
Heparanase extent 2.76 .053 0.99–7.75
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of these tumors (Tstage and grade criteria; Table 2), suggest-
ing an important role of the enzyme in the etiology of this type
of malignancy. In agreement with this notion was the inverse
correlation found between heparanase expression levels and
the survival of SCCHN patients (Figure 2, Table 3). This
observation is in agreement with previous findings analyzing
17 cases of primary SCCHN and the localization of hepa-
ranase to the invasion front of these tumors [30]. Even more
impressive was the correlation between the cellular locali-
zation of heparanase and patient survival. Clearly, nuclear
localization of heparanase predicts a favorable outcome,
whereas cytoplasmic localization of the enzyme correlates
with poor prognosis (Figure 3, Tables 3–6). We further
employed the Cox’s proportional hazard model statistical
analysis and demonstrated that cytoplasmic versus nuclear
heparanase localization, age, T stage, and N stage are
the most significant parameters that affect the survival of
head and neck cancer patients (Table 6). Moreover, hepa-
ranase localization stands as an independent parameter for
patient status (Table 4). Further analysis indicated that hep-
aranase staining extent is a critical parameter that affects
cause-specific survival (Table 7), suggesting that both hep-
aranase expression levels (heparanase extent) and localiza-
tion are crucial for SCCHN tumor progression. These results
support and further extend previous findings correlating
heparanase expression with the poor prognosis of patients
with head and neck [30], as well as colorectal [28], bladder
[39], and cervical [27] carcinomas. The mechanism by
which heparanase contributes to tumor progression is not
entirely clear but likely involves tumor angiogenesis. Hepa-
ranase upregulation in several primary human tumors has
been shown to correlate with increased microvessel den-
sity [24,27,28,40–42], an angiogenic feature that has
been recapitulated in several in vitro [43] and in vivo ex-
perimental settings [44–49]. Moreover, heparanase down-
regulation by specific anti-heparanase ribozyme or siRNA
constructs resulted in xenografts that appeared less vas-
cularized [21], further supporting heparanase as a pro-
angiogenic mediator. More recently, heparanase was found
to induce the expression of vascular endothelial growth
factor in an Src-dependent manner [49], clearly depicting
its angiogenic function. The role that heparanase may play
in the nucleus is less understood. Nuclear localization of
heparanase was demonstrated by cell fractionation [50]
and by immunostaining of cultured cells [50] and tumor
biopsies [26,51]. Notably, nuclear localization was corre-
lated with sustained cellular differentiation and a favorable
outcome in patients with gastric and esophageal carci-
nomas [26,51], in agreement with our study (Tables 3–6,
Figure 3). Gene transcription may be due to a direct inter-
action of nuclear heparanase with DNA or may be a con-
sequence of heparanase-mediated remodeling of nuclear
HS. The latter possibility is supported by a recent publica-
tion by Kobayashi et al. [52] studying the differentiation of
esophageal keratinocytes. In this system, heparanase was
noted to be translocated from the cytoplasm to the nucleus
during esophageal cell differentiation, correlating with induc-
tion of keratinocyte differentiation markers such as p27 and
involucrin. Notably, p27 and involucrin induction was signifi-
cantly reduced on inhibition of heparanase activity by a novel
pharmacological inhibitor SF4 [52], suggesting that HS
remodeling by heparanase directly affects gene expression,
in agreement with previous studies demonstrating nuclear
localization of HS [53,54]. Moreover, transfection of breast
carcinoma MCF-7 cells with a plasmid vector that targets
heparanase exclusively to the nucleus induced the appear-
ance of lipid droplets typical of differentiated mammary
epithelial cells [55], thus further supporting a role for hepa-
ranase in epithelial cell differentiation. Taken together, our
results indicate that heparanase expression is enhanced in
head and neck tumors and that the outcome of these patients
correlates with heparanase levels and with its cellular local-
ization. These findings are novel and contribute to our under-
standing of head and neck tumor biology, suggesting that
heparanase is a promising target for the development of
anticancer therapeutics for head and neck malignancies.
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